These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 10202188)

  • 1. Antitumor effects of interleukin-12 in pre-clinical and early clinical studies (Review).
    Golab J; Zagozdzon R
    Int J Mol Med; 1999 May; 3(5):537-44. PubMed ID: 10202188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer.
    Tahara H; Lotze MT
    Gene Ther; 1995 Mar; 2(2):96-106. PubMed ID: 7719935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual stimulatory and inhibitory effect of NK cell stimulatory factor/IL-12 on human hematopoiesis.
    Bellone G; Trinchieri G
    J Immunol; 1994 Aug; 153(3):930-7. PubMed ID: 7517976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antitumoral action of interferons and interleukins in combination with radiotherapy. Part I: immunologic basis].
    Herskind C; Fleckenstein K; Lohr J; Li CY; Wenz F; Lohr F
    Strahlenther Onkol; 2004 Apr; 180(4):187-93. PubMed ID: 15057428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin 15 as a promising candidate for tumor immunotherapy.
    Jakobisiak M; Golab J; Lasek W
    Cytokine Growth Factor Rev; 2011 Apr; 22(2):99-108. PubMed ID: 21531164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF.
    Robertson MJ; Soiffer RJ; Wolf SF; Manley TJ; Donahue C; Young D; Herrmann SH; Ritz J
    J Exp Med; 1992 Mar; 175(3):779-88. PubMed ID: 1346796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing effect of natural killer cell stimulatory factor (NKSF/interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells.
    Chehimi J; Valiante NM; D'Andrea A; Rengaraju M; Rosado Z; Kobayashi M; Perussia B; Wolf SF; Starr SE; Trinchieri G
    Eur J Immunol; 1993 Aug; 23(8):1826-30. PubMed ID: 8102101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Function and molecular structure of IL-12].
    Oshimi K; Hoshino S
    Nihon Rinsho; 1992 Aug; 50(8):1840-4. PubMed ID: 1359171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-18: biology and role in the immunotherapy of cancer.
    Srivastava S; Salim N; Robertson MJ
    Curr Med Chem; 2010; 17(29):3353-7. PubMed ID: 20712569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells.
    D'Andrea A; Rengaraju M; Valiante NM; Chehimi J; Kubin M; Aste M; Chan SH; Kobayashi M; Young D; Nickbarg E
    J Exp Med; 1992 Nov; 176(5):1387-98. PubMed ID: 1357073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural killer (NK) cell stimulatory factor increases the cytotoxic activity of NK cells from both healthy donors and human immunodeficiency virus-infected patients.
    Chehimi J; Starr SE; Frank I; Rengaraju M; Jackson SJ; Llanes C; Kobayashi M; Perussia B; Young D; Nickbarg E
    J Exp Med; 1992 Mar; 175(3):789-96. PubMed ID: 1346797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 12: still a promising candidate for tumor immunotherapy?
    Lasek W; Zagożdżon R; Jakobisiak M
    Cancer Immunol Immunother; 2014 May; 63(5):419-35. PubMed ID: 24514955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interleukin-12: potential role in cancer therapy.
    Brunda MJ; Gately MK
    Important Adv Oncol; 1995; ():3-18. PubMed ID: 7672811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-12.
    Germann T; Rüde E
    Int Arch Allergy Immunol; 1995 Oct; 108(2):103-12. PubMed ID: 7549496
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localized Interleukin-12 for Cancer Immunotherapy.
    Nguyen KG; Vrabel MR; Mantooth SM; Hopkins JJ; Wagner ES; Gabaldon TA; Zaharoff DA
    Front Immunol; 2020; 11():575597. PubMed ID: 33178203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells.
    Wolf SF; Temple PA; Kobayashi M; Young D; Dicig M; Lowe L; Dzialo R; Fitz L; Ferenz C; Hewick RM
    J Immunol; 1991 May; 146(9):3074-81. PubMed ID: 1673147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of IL-12 to cytokine therapy and gene therapy for tumors.
    Nishimura T; Watanabe K; Yahata T; Uede T; Saiki I; Herrmann SH; Kobayashi M; Habu S
    Ann N Y Acad Sci; 1996 Oct; 795():375-8. PubMed ID: 8958959
    [No Abstract]   [Full Text] [Related]  

  • 18. Impact of IL-12 in Cancer.
    Lu X
    Curr Cancer Drug Targets; 2017; 17(8):682-697. PubMed ID: 28460617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancement of interleukin-12 gene-based tumor immunotherapy by the reduced secretion of p40 subunit and the combination with farnesyltransferase inhibitor.
    Jin HT; Youn JI; Kim HJ; Lee JB; Ha SJ; Koh JS; Sung YC
    Hum Gene Ther; 2005 Mar; 16(3):328-38. PubMed ID: 15812228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor activities of IL-12 and mechanisms of action.
    Shurin MR; Esche C; Péron JM; Lotze MT
    Chem Immunol; 1997; 68():153-74. PubMed ID: 9329221
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.